Investor

Selective Insurance Group, Inc. Schedules Earnings Release and Conference Call to Announce 3rd Quarter 2021 Results

Thursday, September 23, 2021 - 9:15pm

BRANCHVILLE, N.J., Sept.23, 2021 /PRNewswire/ --Selective Insurance Group, Inc. (NASDAQ: SIGI) announced it will release its third quarter 2021 financial results after market close on Wednesday, October 27, 2021.

Key Points: 
  • BRANCHVILLE, N.J., Sept.23, 2021 /PRNewswire/ --Selective Insurance Group, Inc. (NASDAQ: SIGI) announced it will release its third quarter 2021 financial results after market close on Wednesday, October 27, 2021.
  • The company will hold a conference call on Thursday, October 28, 2021, at 9:00 a.m. (ET) to discuss the results.
  • A press release and financial supplement will also be available on the Investors page of Selective's website after market close on October 27, 2021.
  • Selective Insurance Group, Inc. is a holding company for 10 property and casualty insurance companies rated "A" (Excellent) by AM Best.

Cytokinetics to Host Analyst & Investor Day on October 7, 2021

Thursday, September 23, 2021 - 9:00pm

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host an Analyst and Investor Day on Thursday, October 7, 2021 from 8:30 AM to 11:30 AM ET.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host an Analyst and Investor Day on Thursday, October 7, 2021 from 8:30 AM to 11:30 AM ET.
  • Members of Cytokinetics senior management will be joined by expert clinicians to provide updates on the companys plans for commercialization and advancing cardiovascular pipeline.
  • Registered attendees may access the live virtual event on the Investors & Media section of Cytokinetics website at www.cytokinetics.com .
  • Cytokinetics expects to start a Phase 3 clinical trial of aficamten in patients with obstructive HCM in Q4 2021.

 Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

Thursday, September 23, 2021 - 4:31pm

Greater increases in HFMSE (non-ambulatory) and Revised Hammersmith Scale (ambulatory) scores were seen in patients who were not limited by scoliosis or joint contractures.

Key Points: 
  • Greater increases in HFMSE (non-ambulatory) and Revised Hammersmith Scale (ambulatory) scores were seen in patients who were not limited by scoliosis or joint contractures.
  • Virtual poster presentations (LBP.10 and EP.277) on September 23, 2021, at 16:30-18:30 BST
    E-Posters available to view on demand and exhibition area open starting Monday, September 20, 2021.
  • Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA.
  • Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.

Plus Therapeutics to Present Rhenium-186 NanoLiposome Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting

Thursday, September 23, 2021 - 12:30pm

AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the Company), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data regarding its Rhenium-186 NanoLiposome (186RNL) investigational radiotherapeutic for recurrent glioblastoma (GBM) at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting being held in person October 24-27, 2021 in Chicago, Illinois.

Key Points: 
  • AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the Company), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data regarding its Rhenium-186 NanoLiposome (186RNL) investigational radiotherapeutic for recurrent glioblastoma (GBM) at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting being held in person October 24-27, 2021 in Chicago, Illinois.
  • Where: Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets.
  • Central to the Companys drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases.
  • This press release contains statements that may be deemed forward-looking statements within the meaning of U.S. securities laws.

TG Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

Thursday, September 23, 2021 - 12:30pm

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Chairman and Chief Executive Officer, will participate in a fireside chat during the 2021 Cantor Virtual Healthcare Conference, taking place September 27 30, 2021.

Key Points: 
  • NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Chairman and Chief Executive Officer, will participate in a fireside chat during the 2021 Cantor Virtual Healthcare Conference, taking place September 27 30, 2021.
  • The fireside chat is scheduled to take place on Monday, September 27, 2021 at 10:40 AM ET.
  • TG Therapeuticsis a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • UKONIQ is a registered trademark of TG Therapeutics, Inc.

Tilray to Announce First Quarter Fiscal 2022 Financial Results on October 7, 2021

Thursday, September 23, 2021 - 2:00pm

Tilray, Inc. (Tilray or the Company) (NASDAQ: TLRY; TSX: TLRY) announced that the Company will release financial results for its first quarter fiscal 2022 ended August 31, 2021 before financial markets open on Thursday, October 7, 2021.

Key Points: 
  • Tilray, Inc. (Tilray or the Company) (NASDAQ: TLRY; TSX: TLRY) announced that the Company will release financial results for its first quarter fiscal 2022 ended August 31, 2021 before financial markets open on Thursday, October 7, 2021.
  • Tilray executives will host a conference call and live audio webcast to discuss these results at 8:30 am Eastern Time, details of which are provided below.
  • Live Conference Call and Audio Webcast:
    Date/Time: Thursday, October 7, 2021 at 8:30 am Eastern Time.
  • The Q&A platform for Tilrays upcoming conference call on October 7, 2021, will remain open until 24 hours beforehand.

The Hartford Announces $1 Million Scholarship Fund For UConn Hartford Students

Thursday, September 23, 2021 - 1:00pm

The Hartford has committed $1 million to provide funding for 50 UConn Hartford students who are residents of the City of Hartford.

Key Points: 
  • The Hartford has committed $1 million to provide funding for 50 UConn Hartford students who are residents of the City of Hartford.
  • We are proud to support incoming students in our namesake city as they begin their studies at UConn Hartford, said The Hartfords President Doug Elliot.
  • Mark Overmyer-Velzquez, Ph.D., director of UConn Hartford said, UConn Hartford extends our sincerest appreciation to our neighbor in the city, The Hartford, for their generous gift and meaningful partnership.
  • The Hartford Scholars Program will ultimately provide support and mentoring opportunities to 50 students who live in the City of Hartford and attend the UConn Hartford campus.

ADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

Thursday, September 23, 2021 - 12:15pm

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com .

Key Points: 
  • A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com .
  • ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs).
  • In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

Hilton Grand Vacations and Habitat for Humanity Announce New National Partnership

Thursday, September 23, 2021 - 3:00pm

Hilton Grand Vacations Inc. (NYSE:HGV) recently announced Habitat for Humanity International as the newest national partner in its corporate social responsibility program HGV Serves .

Key Points: 
  • Hilton Grand Vacations Inc. (NYSE:HGV) recently announced Habitat for Humanity International as the newest national partner in its corporate social responsibility program HGV Serves .
  • Hilton Grand Vacations and Habitat for Humanity have a shared commitment to building strong and thriving communities, said Julie Laird Davis, vice president of Corporate and Foundation Relations at Habitat for Humanity.
  • About Hilton Grand Vacations Inc.
    Hilton Grand Vacations Inc. (NYSE:HGV) is recognized as a leading global timeshare company.
  • With headquarters in Orlando, Florida, Hilton Grand Vacations develops, markets and operates a system of brand-name, high-quality vacation ownership resorts in select vacation destinations.

UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference

Thursday, September 23, 2021 - 1:00pm

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the Cantor Fitzgerald 2021 Virtual Global Healthcare Conference on Thursday, September 30, 2021, at 3:20 p.m. Eastern Time.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the Cantor Fitzgerald 2021 Virtual Global Healthcare Conference on Thursday, September 30, 2021, at 3:20 p.m. Eastern Time.
  • A live webcast of the presentation will be available via the Investors section of UroGens website, www.urogen.com .
  • A replay of the webcast will be available on the Companys website for approximately 30 days.
  • UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options.